<DOC>
	<DOCNO>NCT01534884</DOCNO>
	<brief_summary>This randomize , control , multicenter , 2-arm , parallel-group , double-blind , prospective , Phase 1 study design demonstrate comparable pharmacokinetics term AUC0-last Cmax ( second infusion ) CT-P10 MabThera patient active RA concomitantly treat MTX Core Study Period .</brief_summary>
	<brief_title>Demonstrate Equivalence CT-P10 MabThera With Respect Pharmacokinetic Profile Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Patient diagnosis RA accord revised 1987 ACR classification criterion ( Arnett et al 1987 ) least 6 month prior randomization . 2 . Patient active disease define presence 6 swollen joint ( 66 assess ) 6 tender joint ( 68 assess ) , serum CRP ≥1.5 mg/dL ESR ≥28 mm/hour . 1 . Patient unresponsive intolerable 2 biologic agent . 2 . Patient allergy hypersensitivity murine , chimeric , human , humanized protein . 3 . Patient current past history chronic infection hepatitis B , hepatitis C , infection human immunodeficiency virus ( HIV ) 1 2 positive result screen test infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>RA , Biosimilar</keyword>
</DOC>